Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment

FIELD: medicine.

SUBSTANCE: probiotic strain of Enterococcus faecium L-3 is used. Therapy is carried out by short courses (up to a month) with interruptions under the control of the intestinal microbiota composition and the populations of circulating T cells. In case of exacerbations, traditional therapy with copaxone can be used (the use of a probiotic should be stopped for this period).

EFFECT: method allows to increase the effectiveness of treatment by stimulating the production of anti-inflammatory cytokine.

5 dwg



Same patents:

FIELD: biotechnology.

SUBSTANCE: biologically active peptide is obtained, which has curative effect against Alzheimer disease, and consisting of the amino acid sequence Ala-Trp-Lys-Val-Leu-Ser-Pro-Gln-Gly-Gly-Gly-Pro-Trp-Asp-Ser-Val-Ala.

EFFECT: invention enables to use the resulting peptide to create a drug effective in the therapy of Alzheimer disease.

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a hexapeptide of formula Thr-Gly-Glu-Asn-His-Arg-NH2, having neuroprotective and nootropic activity. Disclosed novel pharmaceutical composition based on a peptide, which is highly effective in low doses and is used as nasal drops.

EFFECT: high efficiency in preventing and treating neurodegenerative and cerebrovascular diseases.

2 cl, 3 dwg, 6 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel water-soluble potassium salt of N-(4-acetoxybenzoyl)glycine of formula

given below, which possesses cerebroprotective activity.

EFFECT: invention can be used in chemical-pharmaceutical industry for obtaining effective cerebroprotective medications.

2 dwg, 3 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of structural formula


having Aβ42 secretion inhibiting activity. In formula I , hetaryl I is a five- or six-member heteroaryl group containing 1-3 heteroatoms selected from O, S or N, hetaryl II is a five- or six-member heteroaryl group containing 1-3 heteroatoms as defined above for hetaryl I, or is a bicyclic ring system containing 1-4 heteroatoms selected from S, O or N, where at least one ring is aromatic by nature, R1 is C1-7-alkyl, C1-7-alkoxy, C1-7-alkyl substituted with a halogen, or a halogen; R2 is a halogen, C1-7-alkyl, C1-7-alkoxy, hydroxy, C1-7-alkyl substituted with a halogen, C1-7-alkyl substituted with a hydroxy, or benzo[1,3]dioxolyl or is -(CHR)p-phenyl, optionally substituted with a halogen, C1-7-alkyl, C1-7-alkoxy, S(O)2-C1-7-alkyl, cyano, nitro, C1-7-alkoxy substituted with a halogen, dimethylamino, -(CH2)p-NHC(O)O-C1-7-alkyl or C1-7-alkyl, substituted with a halogen. The values of radicals R, R3, R4,p, n, m, o are given in the claim.

EFFECT: invention relates to a method of producing said compounds, a medicinal agent containing said compounds and a method of treating Alzheimer's disease, cerebral amyloid angiopathy, Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), vascular dementia, dementia pugilistica or Down syndrome, associated with β amyloid activity.

21 cl, 283 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with the application of at least one peptide, selected from the group, including SEFKHG(C), TLHEFRH(C), ILFRHG(C), TSVFRH(C), SQFRHY(C), LMFRHN(C), SPNQFRH(C), ELFKHHL(C), THTDFRH(C), DEHPFRH(C), QSEFKHW(C), ADHDFRH(C), YEFRHAQ(C) and TEFRHKA(C), for the production of a medication for the prevention and/or treating Alzheimer's disease. The group of inventions relates a vaccine, containing at least one said peptide, intended for the induction of immune response aimed against Aβ.

EFFECT: group of invention provides the favourable effect of vaccination with vaccines with mimotopes in the treatment of Alzheimer's disease.

24 cl, 3 ex, 10 dwg, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biotechnology and immunology. What is presented is a hybridoma cell line FP12H3-C2 deposited under No. DSM ACC2750 producing the anti-beta-amyloid antibody. Presented are methods for preparing an antibody, including a humanised antibody with using a hybridoma line according to the invention, as well as diagnostic techniques for a beta-amyloid associated disease or condition in a patient or a liability to such disease or condition, a method for determining a degree of the tissue involvement into amyloidogenic plaques, a method for monitoring minimal residual signs of the disease into a patient following treating with the antibody or its active fragment, a method for prediction of sensitivity in the patient treated with the antibody or its active fragment.

EFFECT: present invention can find further application in diagnosing and therapy of beta-amyloid related diseases, such as Alzheimer disease.

9 cl, 4 dwg, 5 tbl, 17 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a pharmaceutical composition based on a compound of formula (I) or its pharmaceutically acceptable salt or solvate. wherein X is S or O, and provided X is S, R1 is OH or NH2; and provided X is O, R1 is OH, NH2 or NHMe. The invention also refers to a compound of formula (I) and a based kit.

EFFECT: there are prepared new imidazolidine derivatives effective in treating prostate cancer.

28 cl, 14 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition for treating insomnia. Said composition includes root of Polygonum multiflorum and/or its extracts, seeds of Ziziphus spinosa and/or its extracts, mulberry fruit and/or its extracts, Ganoderma and/or its extracts, lily bulb and/or its extracts, Anemarrhena rhizome and/or its extracts, root of Salvia miltiorrhiza and/or its extracts, chrysanthemum flower and/or its extracts, Poria and/or its extracts and Albizia flower and/or its extracts. Invention also relates to application of said composition.

EFFECT: claimed invention provides sedative and soporific effect, contributes to memory stimulation.

17 cl, 6 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.

EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.

12 cl, 3 tbl, 21 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biochemistry, in particular to cyclic peptide, capable of inducing antibody response. Peptide consists of formula X2X3VGSNK-Z or X3VGSNKG-Z, where X2 represents E, G, Q or K, X3 represents D or N and Z represents agent, stabilising bent, present inside peptide sequence, with peptide being cyclised by covalent bonding of N-end amino acid with Z, where Z represents peptide fragment YNGK. Conjugate, containing said cyclic peptide, conjugated with immunogenic carrier molecule is also claimed. peptide and conjugate, which contains it, can be applied for production of medication or as vaccine against Alzheimer's disease. Methods of obtaining cyclic peptide and conjugate are also claimed.

EFFECT: invention makes it possible to obtain improved, less toxic vaccine against Alzheimer's disease.

8 cl, 11 dwg, 1 tbl, 2 ex

FIELD: biotechnology.

SUBSTANCE: strain is deposited in the State collection of pathogenic microorganisms "SCIM-Obolensky" under the number F-11. The culture fluid centrate obtained as a result of culturing of said the strain on the liquid nutrient medium has high activity against anthrax causative agent. The zone of inhibition of growth of Bacillus anthracis is 20-25 mm and 35-45 mm when the culture fluid centrate of the said strain is used in an amount of 10 mcl and 100 mcl, respectively.

EFFECT: strain of micromycete Trichoderma hamatum has antibacterial activity against anthrax causative agent Bacillus anthracis.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at controlling demodectic mange in cattle. As an insectoacaricide, a composition is used in the following mixture ratio, wt %: abamectin - 0.1; fipronil - 0.5; dimehyl sulphoxide - 10; ethyl cellulose - 30-40; polyethylene glycol - 1,500 - 16; isopropyl alcohol - the rest up to 100. The composition is used by local applications on the affected areas of the animal's skin.

EFFECT: method enables increasing the therapeutic effectiveness in treating demodectic mange in cattle.

1 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: insecticidal-acaricidal agent is used as a composition with the following ratio of components, wt %: abamectin - 0.1; fipronyl - 0.5; dimethyl sulfoxide - 10; ethyl-cellulose - 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest to 100. The composition is used by the method of application to the region of dewlap, shoulder, hip and abdomen in a dose of 20 ml per animal.

EFFECT: method enables to increase the efficiency of protection of cattle from ixodic ticks.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to the strain of Bifidobacterium longum NCIMB 41675, a composition, containing thereof, and a food product, containing the said strain or composition. The claimed strain possesses an ability to induce the production of cytokins and control IL-10:IL-12 ratio is suitable for application in immunomodulation, treatment of an autoimmune disease.

EFFECT: claimed strain, composition and food product possess probiotic properties.

25 cl, 16 dwg, 4 tbl, 8 ex

FIELD: biotechnology.

SUBSTANCE: method of production of probiotic preparation of immobilised bifidobacteria for feeding beef breed cattle is proposed. The bifidobacteria of strain Bifidobacterium longum are grown on a nutrient medium to obtain biotitre of 108-109 CFU/ml. The medium is prepared using the electro-activated cathode water with pH 8-9 and redox potential -400…-500 mV, and with the addition of a stabiliser - serine in an amount of not less than 0.01 wt %. Then bifidobacteria together with the components of the nutrient medium are immobilised on enterosorbent polyphepan.

EFFECT: improved appetite of cattle, digestibility of nutrients of the ration, increase in average daily gain, stimulation of rumen digestion, normalisation of all types of metabolism, acceleration of the settlement of the gastrointestinal tract with normal microflora, reduction of excretion with faeces of pathogenic and opportunistic pathogenic bacteria.

4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates for composition for treatment or prevention of disorders, associated with reduced level of defensins. Composition contains from 0.005 to 1000 mg of Lactobacillus johnsonii Lal (NCC533, No CNCM 1-1225) per a daily dose, with at least 90% of L. johnsonii Lal (NCC533, No CNCM 1-1225) being transferred into state in which they become non-replicating at temperature110-140°C for 5-30 s.

EFFECT: invention provides enhancement of expression of defensin hBD1 mRNA.

5 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with an immunobiological agent for treating urinary bladder cancer, based on BCG vaccine, including a peptidoglycan fragment, which contains diaminopimelic acid as a part of its structure. The group of inventions also deals with a method of applying the claimed immunobiological agent for the treatment of urinary bladder cancer.

EFFECT: group of inventions provides an increased anti-tumour activity.

5 cl, 5 ex, 5 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deals with composition, possessing property to stimulate antimicrobial defence by increasing expression of endogenous β-defensins, containing strain B. longum NCC 2705, depositary number CNCM 1-2618, with said strain being brought, at least, partially into non-replicable condition by thermal inactivation, processing , at least, about 70°C. Method of stimulating endogenous antimicrobial activity of mammal by increasing expression of endogenous β-defensins, includes introduction of claimed composition.

EFFECT: group of inventions provides increase of efficiency in comparison with live strains.

12 cl, 2 dwg

FIELD: chemistry.

SUBSTANCE: group of inventions relates to biotechnology. Claimed is a strain of Bacillus subtilis Maseca-1, producing a peptide, which has the antimicrobial activity against Micrococcus luteus, Bacillus cereus and Aspergillus flavus. The strain is deposited in ATCC under number PTA-8831. The strain was isolated from pericarp of nixtamalised corn. Also claimed is a method of inhibiting Micrococcus luteus, Bacillus cereus and Aspergillus flavus in a material, containing or subjected to the action of the said microorganisms. The method includes the impact of an effective quantity of the said strain on the material.

EFFECT: group of inventions provides the effective inhibition of the growth of pathogenic microorganisms Micrococcus luteus, Bacillus cereus and Aspergillus flavus.

5 cl, 13 dwg, 7 tbl

FIELD: medicine.

SUBSTANCE: invention is intended for prevention of post-infectious irritable bowel syndrome (PI-IBS). Peroral intake of autoprobiotic, representing individual lactic product, prepared on the basis of Enterococcus faecium strain, and containing 108 CFU in 1 ml of product. Inoculation of bacteria from patient's feces on selective nutritional medium is performed, with further culture growing in selective nutritional medium, identification and selection of colonies, typical for Enterococcus faecium, obtaining pure culture of Enterococcus faecium and specification of species and content of pathogenecity factors by method of polymerase chain reaction, selection of apatogenic clones of Enterococcus faecium, corresponding to standards of genetic safety and physiological functionality, which are used to prepare lactic starter culture. Autoprobiotic is introduced in dose not less than 100 ml/day, with course constituting not fewer than 10 days. Selected apathogenic clones of Enterococcus faecium are deposited in cryostorage at temperature not higher than -75°C with storage term not longer than 1 year. Enterococcus-agar is used as selective nutritional medium.

EFFECT: method makes it possible to increase efficiency of prophylaxis of PI-IBS patients due to reduction of its development frequency.

3 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex